Pomalidomide is a thalidomide analogue used in combination with dexamethasone to treat patients with multiple myeloma. FDA approved on February 8, 2013.
- Mechanism
- Curator reviewed
Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells. Furthermore, promalidomide enhances T cell and natural killer (NK) cell-mediated immunity and inhibited the production of pro-inflammatory cytokines, like TNF-alpha or IL-6, by monocytes. The primary target of promalidomide is thought to be the protein cereblon. It binds to this target and inhibits ubiquitin ligase activity. It is also a transcriptional inhibitor of COX2.
- Primary indication
- Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy.Curator reviewed · 5 structured indications
- Formula / weight
- C13H11N3O4 · 273.2441 g/mol (avg)
- First approval
- Canada, 2023 · United States, 2013 · European Union, 2016
- Code names
- CC-4047
- Brand names
Resolves to
UVSMNLNDYGZFPF-UHFFFAOYSA-NSMILESNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=OWhat you can answer from here — as of September 22, 2025
Which drugs share a target with Pomalidomide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account